Diagnosis and treatment of low-renin hypertension

Clinical Endocrinology

Volumn 67, Issue 3, 2007, Pages 324-334

  Mulatero, Paolo ^a,b   Verhovez, Andrea ^b   Morello, Fulvio ^b   Veglio, Franco ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; AMILORIDE; CYTOCHROME P450; CYTOCHROME P450 CYP11B1; DEXAMETHASONE; EPLERENONE; HYDROCHLOROTHIAZIDE; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PROTEIN KINASE WNK1; RENIN; SPIRONOLACTONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; DIFFERENTIAL DIAGNOSIS; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GORDON SYNDROME; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LIDDLE SYNDROME; LOW RENIN HYPERTENSION; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTENSION, RENAL; RENIN;

EID: 34548015418     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02898.x     Document Type: Article

References (114)

1. Laragh, J.H. (1973) Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. American Journal of Medicine, 55, 261 274.
2. Gordon, R.D., Laragh, J.H. Funder, J.W. (2005) Low-renin hypertensive states: perspectives, unsolved problems, future research. Trends in Endocrinology and Metabolism, 16, 108 113.
3. Sealey, J.E., Gordon, R.D. Mantero, F. (2005) Plasma renin and aldosterone measurements in low-renin hypertensive states. Trends in Endocrinology and Metabolism, 16, 86 91.
4. Morimoto, A., Uzu, T., Fujii, T., Nishimura, M., Kuroda, S., Nakamura, S., Inenaga, T. Kimura, G. (1997) Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet, 350, 1734 1737.
5. Milliez, P., Girerd, X., Plouin, P.F., Blacher, J., Safar, M.E. Mourad, J.J. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology, 45, 1243 1248.
6. Lifton, R.P., Gharavi, A.G. Geller, D.S. (2001) Molecular mechanisms of human hypertension. Cell, 104, 545 556.
7. Fisher, N.D., Hurwitz, S., Jeunemaitre, X., Hopkins, P.N., Hollenberg, N.K. Williams, G.H. (2002) Familial aggregation of low-renin hypertension. Hypertension, 39, 914 918.
8. Mulatero, P., Milan, A., Williams, T.A. Veglio, F. (2006) Mineralocorticoid receptor blockade in the protection of target organ damage. Cardiovascular & Hematological Agents in Medicinal Chemistry, 4, 75 91.
9. Maule, S., Mulatero, P., Milan, A., Leotta, G., Caserta, M., Bertello, C., Rabbia, F. Veglio, F. (2006) QT interval in patients with primary aldosteronism and low-renin essential hypertension. Journal of Hypertension, 24, 2459 2464.
10. Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G. Mulatero, P. (2006) Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 91, 454 459.
11. Nishizaka, M.K., Zaman, M.A., Green, S.A., Renfroe, K.Y. Calhoun, D.A. (2004) Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation, 109, 2857 2861.
12. Rossi, G.P., Bernini, G., Desideri, G., Fabris, B., Ferri, C., Giacchetti, G., Letizia, C., Maccario, M., Mannelli, M., Matterello, M.J., Montemurro, D., Palombo, G., Tizzoni, D., Rossi, E., Pessina, A.C., Mantero, F. PAPY Study Participants 2006) Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension, 48, 232 238.
13. Kozakova, M., Buralli, S., Palombo, C., Bernini, G., Moretti, A., Favilla, S., Taddei, S. Solvetti, A. (2003) Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension, 41, 230 236.
14. Mulatero, P., Stowasser, M., Loh, K.C., Fardella, C.E., Gordon, R.D., Mosso, L., Gomez-Sanchez, C.E., Veglio, F. Young, W.F. Jr. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. Journal of Clinical Endocrinology and Metabolism, 89, 1045 1050.
15. Stowasser, M., Gordon, R.D., Gunasekera, T.G., Cowley, D.C., Ward, G., Archibald, C. Smithers, B.M. (2003) High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. Journal of Hypertension, 21, 2149 2157.
16. Stowasser, M. Gordon, R.D. (2003) Primary aldosteronism: from genesis to genetics. Trends in Endocrinology and Metabolism, 14, 310 317.
17. Loh, K.C., Koay, E.S., Khaw, M.C., Emmanuel, S.C. Young, W.F. Jr. (2000) Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. Journal of Clinical Endocrinology and Metabolism, 85, 2854 2859.
18. Rossi, E., Regolisti, G., Negro, A., Sani, C., Davoli, S. Perazzoli, F. (2002) High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. American Journal of Hypertension, 15, 896 902.
19. Fardella, C.E., Mosso, L., Gomez-Sanchez, C., Cortes, P., Soto, J., Gomez, L., Pinto, M., Huete, A., Oestreicher, E., Foradori, A. Montero, J. (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. Journal of Clinical Endocrinology and Metabolism, 85, 1863 1867.
20. Mosso, L., Carvajal, C., Gonzalez, A., Barraza, A., Avila, F., Montero, J., Huete, A., Gederlini, A. Fardella, C.E. (2003) Primary aldosteronism and hypertensive disease. Hypertension, 42, 161 165.
21. Rossi, G.P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., Mallamaci, F., Mannelli, M., Matterello, M.J., Moretti, A., Palombo, G., Parenti, G., Porteri, E., Semplicini, A., Rizzoni, D., Rossi, E., Boscaro, M., Pessina, A.C. Mantero, F. (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology, 48, 2293 2300.
22. Mulatero, P., Rabbia, F., Milan, A., Paglieri, C., Morello, F., Chiandussi, L. Veglio, F. (2002) Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension, 40, 897 902.
23. Mulatero, P., Milan, A., Rabbia, F., Garrone, C., Rossato, D. Veglio, F. (2005) Diagnosis of surgically-treatable forms of primary aldosteronism. Current Hypertension Reviews, 1, 259 266.
24. Mulatero, P., Dluhy, R.G., Giacchetti, G., Boscaro, M., Veglio, F. Stewart, P.M. (2005) Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends in Endocrinology and Metabolism, 16, 114 119.
25. Mulatero, P., Milan, A., Fallo, F., Regolisti, G., Pizzolo, F., Fardella, C., Mosso, L., Marafetti, L., Veglio, F. Maccario, M. (2006) Comparison of confirmatory tests for the diagnosis of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 91, 2618 2623.
26. Connell, J.M., Fraser, R., MacKenzie, S. Davies, E. (2003) Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension, 41, 993 999.
27. Stowasser, M., Gordon, R.D., Rutherford, J.C., Nikwan, N.Z., Daunt, N. Slater, G.J. (2001) Diagnosis and management of primary aldosteronism. Journal of the Renin Angiotensin Aldosterone System, 2, 156 169.
28. Magill, S.B., Raff, H., Shaker, J.L., Brickner, R.C., Knechtges, T.E., Kehoe, M.E. Findling, J.W. (2001) Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism, 86, 1066 1071.
29. Young, W.F., Stanson, A.W., Thompson, G.B., Grant, C.S., Farley, D.R. van Heerden, J.A. (2004) Role for adrenal venous sampling in primary aldosteronism. Surgery, 136, 1227 1235.
30. Sutherland, D.J.A., Ruse, J.C. Laidlaw, J.C. (1966) Hypertension increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Canadian Medical Association Journal, 95, 1109 1119.
31. Mulatero, P., Veglio, F., Pilon, C., Rabbia, F., Zocchi, C., Limone, P., Boscaro, M., Sonino, N. Fallo, F. (1998) Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. Journal of Clinical Endocrinology and Metabolism, 83, 2573 2575.
32. Litchfield, W.R., Coolidge, C., Silva, P., Lifton, R.P., Fallo, F., Williams, G.H. Dluhy, R.G. (1997) Impaired potassium-stimulated aldosterone production: a possible explanation for normokalemic glucocorticoid-remediable aldosteronism. Journal of Clinical Endocrinology and Metabolism, 82, 1507 1510.
33. Litchfield, W.R., Anderson, B.F., Weiss, J., Lifton, R.P. Dluhy, R.G. (1998) Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension, 31, 445 450.
34. Lifton, R.P., Dluhy, R.G., Powers, M., Rich, G.M., Cook, S., Ulick, S. Lalouel, J.M. (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature, 355, 262 265.
35. Mulatero, P., Morello, F. Veglio, F. (2004) Genetics of primary aldosteronism. Journal of Hypertension, 22, 663 670.
36. Dluhy, R.G., Anderson, B., Harlin, B., Ingelfinger, J. Lifton, R. (2001) Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. Journal of Pediatrics, 138, 715 720.
37. Wyckoff, J.A., Seely, E.W., Hurwitz, S., Anderson, B.F., Lifton, R.P. Dluhy, R.G. (2000) Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension, 35, 668 672.
38. Mulatero, P., Morra Di Cella, S., Williams, T.A., Milan, A., Mengozzi, G., Chiandussi, L., Gomez-Sanchez, C.E. Veglio, F. (2002) Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation italian pedigree. Journal of Clinical Endocrinology and Metabolism, 87, 3187 3191.
39. Fallo, F., Pilon, C., Williams, T.A., Sonino, N., Morra Di Cella, S., Veglio, F., De Iasio, R., Montanari, P. Mulatero, P. (2004) Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. Journal of Human Hypertension, 18, 47 51.
40. Mulatero, P., Curnow, K.M., Aupetit-Faisant, B., Foekling, M., Gomez-Sanchez, C., Veglio, F., Jeunemaitre, X., Corvol, P. Pascoe, L. (1998) Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. Journal of Clinical Endocrinology and Metabolism, 83, 3996 4001.
41. Stowasser, M., Bachmann, A.W., Huggard, P.R., Rossetti, T.R. Gordon, R.D. (2000) Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. Journal of Clinical Endocrinology and Metabolism, 85, 3313 3318.
42. McMahon, G.T. Dluhy, R.G. (2004) Glucocorticoid-remediable aldosteronism. Cardiology Reviews, 12, 44 48.
43. Torpy, D.J., Gordon, R.D., Lin, J.P., Huggard, P.R., Taymans, S.E., Stowasser, M., Chrousos, G.P. Stratakis, C.A. (1998) Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. Journal of Clinical Endocrinology and Metabolism, 83, 3214 3218.
44. Kahle, K.T., Wilson, F.H. Lifton, R.P. (2005) Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. Trends in Endocrinology and Metabolism, 16, 98 103.
45. Disse-Nicodeme, S., Desitter, I., Fiquet-Kempf, B., Houot, A.M., Stern, N., Delahousse, M., Potier, J., Ader, J.L. Jeunemaitre, X. (2001) Genetic heterogeneity of familial hyperkalaemic hypertension. Journal of Hypertension, 19, 1957 1964.
46. Tobin, M.D., Raleigh, S.M., Newhouse, S., Braund, P., Bodycote, C., Ogleby, J., Cross, D., Gracey, J., Hayes, S., Smith, T., Ridge, C., Caulfield, M., Sheehan, N.A., Munroe, P.B., Burton, P.R. Samani, N.J. (2005) Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation, 112, 3423 3429.
47. Oster, J.R., Singer, I. Fishman, L.M. (1995) Heparin-induced aldosterone suppression and hyperkalemia. American Journal of Medicine, 98, 575 586.
48. Abdel-Raheem, M.M., Potti, A., Tadros, S., Koka, V., Hanekom, D., Fraiman, G. Danielson, B.D. (2003) Effect of low-molecular-weight heparin on potassium homeostasis. Pathophysiology of Haemostasis and Thrombosis, 32, 107 110.
49. Quinkler, M. Stewart, P.M. (2003) Hypertension and the cortisol-cortisone shuttle. Journal of Clinical Endocrinology and Metabolism, 88, 2384 2392.
50. Shimkets, R.A., Warnock, D.G., Bositis, C.M., Nelson-Williams, C., Hansson, J.H., Schambelan, M., Gill, J.R. Jr., Ulick, S., Milora, R.V., Findling, J.W., Canessa, C.M., Rossier, B.C. Lifton, R.P. (1994) Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell, 79, 407 414.
51. Hiltunen, T.P., Hannila-Handelberg, T., Petajaniemi, N., Kantola, I., Tikkanen, I., Virtamo, J., Gautschi, I., Schild, L. Kontula, K. (2002) Liddle's syndrome associated with a point mutation in the extracellular domain of the epithelial sodium channel gamma subunit. Journal of Hypertension, 20, 2383 2390.
52. Inoue, J., Iwaoka, T., Tokunaga, H., Takamune, K., Naomi, S., Araki, M., Takahama, K., Yamaguchi, K. Tomita, K. (1998) A family with Liddle's syndrome caused by a new missense mutation in the beta subunit of the epithelial sodium channel. Journal of Clinical Endocrinology and Metabolism, 83, 2210 2213.
53. Sagnella, G.A. Swift, P.A. (2006) The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure. Current Pharmaceutical Design, 12, 2221 2234.
54. Persu, A., Barbry, P., Bassilana, F., Houot, A.M., Mengual, R., Lazdunski, M., Corvol, P. Jeunemaitre, X. (1998) Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension, 32, 129 137.
55. Baker, E.H., Dong, Y.B., Sagnella, G.A., Rothwell, M., Onipinla, A.K., Markandu, N.D., Cappuccio, F.P., Cook, D.G., Persu, A., Corvol, P., Jeunemaitre, X., Carter, N.D. MacGregor, G.A. (1998) Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. Lancet, 351, 1388 1392.
56. Dong, Y.B., Zhu, H.D., Baker, E.H., Sagnella, G.A., MacGregor, G.A., Carter, N.D., Wicks, P.D., Cook, D.G. Cappuccio, F.P. (2001) T594M and G442V polymorphisms of the sodium channel beta subunit and hypertension in a black population. Journal of Human Hypertension, 15, 425 430.
57. Baker, E.H., Duggal, A., Dong, Y., Ireson, N.J., Wood, M., Markandu, N.D. MacGregor, G.A. (2002) Amiloride, a specific drug for hypertension in black people with T594M variant? Hypertension, 40, 13 17.
58. Rayner, B.L., Owen, E.P., King, J.A., Soule, S.G., Vreede, H., Opie, L.H., Marais, D. Davidson, J.S. (2003) A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. Journal of Hypertension, 21, 921 926.
59. Geller, D.S., Farhi, A., Pinkerton, N., Fradley, M., Moritz, M., Spitzer, A., Meinke, G., Tsai, F.T., Sigler, P.B. Lifton, R.P. (2000) Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science, 289, 119 123.
60. Rafestin-Oblin, M.E., Souque, A., Bocchi, B., Pinon, G., Fagart, J. Vandewalle, A. (2003) The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related. Endocrinology, 144, 528 533.
61. New, M.I., Geller, D.S., Fallo, F. Wilson, R.C. (2005) Monogenic low-renin hypertension. Trends in Endocrinology and Metabolism, 16, 92 97.
62. Wilson, R.C., Nimkarn, S. New, M.I. (2001) Apparent mineralocorticoid excess. Trends in Endocrinology and Metabolism, 12, 104 111.
63. Wilson, R.C., Dave-Sharma, S., Wei, J.Q., Obeyesekere, V.R., Li, K., Ferrari, P., Krozowski, Z.S., Shackleton, C.H., Bradlow, L., Wiens, T. New, M.I. (1998) A genetic defect resulting in mild low-renin hypertension. Proceedings of the National Academy of Sciences, 95, 10200 10205.
64. Lavery, G.G., Ronconi, V., Draper, N., Rabbitt, E.H., Lyons, V., Chapman, K.E., Walker, E.A., McTernan, C.L., Giacchetti, G., Mantero, F., Seckl, J.R., Edwards, C.R., Connell, J.M., Hewison, M. Stewart, P.M. (2003) Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension, 42, 123 129.
65. Li, A., Li, K.X., Marui, S., Krozowski, Z.S., Batista, M.C., Whorwood, C.B., Arnhold, I.J., Shackleton, C.H., Mendonca, B.B. Stewart, P.M. (1997) Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Journal of Hypertension, 15, 1397 1402.
66. Soro, A., Ingram, M.C., Tonolo, G., Glorioso, N. Fraser, R. (1995) Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension, 25, 67 70.
67. Lovati, E., Ferrari, P., Dick, B., Jostarndt, K., Frey, B.M., Frey, F.J., Schorr, U. Sharma, A.M. (1999) Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. Journal of Clinical Endocrinology and Metabolism, 84, 3745 3749.
68. Williams, T.A., Mulatero, P., Filigheddu, F., Truffa, C., Milan, A., Argiolas, G., Parpaglia, P.P., Veglio, F. Glorioso, N. (2005) Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International, 67, 631 637.
69. Rosler, A., Leiberman, E. Cohen, T. (1992) High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco. American Journal of Medical Genetics, 42, 827 834.
70. New, M.I. (2003) Inborn errors of adrenal steroidogenesis. Molecular and Cellular Endocrinology, 211, 75 83.
71. Portrat, S., Mulatero, P., Curnow, K.M., Chaussain, J.L., Morel, Y. Pascoe, L. (2001) Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11beta-hydroxylase) and CYP11B2 (aldosterone synthase) cause steroid 11beta-hydroxylase deficiency and congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 86, 3197 3201.
72. Zachmann, M., Tassinari, D. Prader, A. (1983) Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. Journal of Clinical Endocrinology and Metabolism, 56, 222 229.
73. Barr, M., Mackenzie, S.M., Friel, E.C., Holloway, C.D., Wilkinson, D.M., Brain, N.J., Ingram, M.C., Fraser, R., Brown, M., Samani, N.J., Caulfield, M., Munroe, P.B., Farrall, M., Webster, J., Clayton, D., Dominiczak, A.F., Connell, J.M.C. Davies, E. (2007) Polymorphic variation in the 11{beta}-hydroxylase gene associates with reduced 11-hydroxylase efficiency. Hypertension, 49, 113 119.
74. Imrie, H., Freel, M., Mayosi, B.M., Davies, E., Fraser, R., Ingram, M., Cordell, H.J., Farrall, M., Avery, P.J., Watkins, H., Keavney, B. Connell, J.M. (2006) Association between aldosterone production and variation in the 11{beta}-hydroxylase (CYP11B1) gene. Journal of Clinical Endocrinology and Metabolism, 91, 5051 5056.
75. Tamaki, S., Iwai, N., Tsujita, Y. Kinoshita, M. (1999) Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension, 33, 266 270.
76. Rossi, E., Regolisti, G., Perazzoli, F., Negro, A., Davoli, S., Nicoli, D., Sani, C. Casali, B. (2001) -344C/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low-renin hypertension. American Journal of Hypertension, 14, 934 941.
77. Mulatero, P., Schiavone, D., Fallo, F., Rabbia, F., Pilon, C., Chiandussi, L., Pascoe, L. Veglio, F. (2000) CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension, 35, 694 698.
78. Mulatero, P., Veglio, F., Maffei, P., Bondanelli, M., Bovio, S., Daffara, F., Leotta, G., Angeli, A., Calvo, C., Martini, C., Degli Uberti, E.C. Terzolo, M. (2006) CYP11B2 -344T/C gene polymorphism and blood pressure in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 5008 5012.
79. Takeda, Y., Yoneda, T., Demura, M., Furukawa, K., Koshida, H., Miyamori, I. Mabuchi, H. (2001) Genetic analysis of the cytochrome P-450c17alpha (CYP17) and aldosterone synthase (CYP11B2) in Japanese patients with 17alpha-hydroxylase deficiency. Clinical Endocrinology, 54, 751 758.
80. Costa-Santos, M., Kater, C.E., Auchus, R.J. Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group 2004) Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 89, 49 60.
81. Costa-Santos, M., Kater, C.E., Dias, E.P. Auchus, R.J. (2004) Two intronic mutations cause 17-hydroxylase deficiency by disrupting splice acceptor sites: direct demonstration of aberrant splicing and absent enzyme activity by expression of the entire CYP17 gene in HEK-293 cells. Journal of Clinical Endocrinology and Metabolism, 89, 43 48.
82. Karl, M., Lamberts, S.W., Detera-Wadleigh, S.D., Encio, I.J., Stratakis, C.A., Hurley, D.M., Accili, D. Chrousos, G.P. (1993) Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. Journal of Clinical Endocrinology and Metabolism, 76, 683 689.
83. Hurley, D.M., Accili, D., Stratakis, C.A., Karl, M., Vamvakopoulos, N., Rorer, E., Constantine, K., Taylor, S.I. Chrousos, G.P. (1991) Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. Journal of Clinical Investigation, 87, 680 686.
84. Charmandari, E., Kino, T., Souvatzoglou, E., Vottero, A., Bhattacharyya, N. Chrousos, G.P. (2004) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. Journal of Clinical Endocrinology and Metabolism, 89, 1939 1949.
85. Mendonca, B.B., Leite, M.V., De Castro, M., Kino, T., Elias, L.L., Bachega, T.A., Arnhold, I.J., Chrousos, G.P. Latronico, A.C. (2002) Female pseudohermaphroditism caused by a novel homozygous missense mutation of the GR gene. Journal of Clinical Endocrinology and Metabolism, 87, 1805 1809.
86. Kino, T., De Martino, M.U., Charmandari, E., Mirani, M. Chrousos, G.P. (2003) Tissue glucocorticoid resistance/hypersensitivity syndromes. Journal of Steroid Biochemistry and Molecular Biology, 85, 457 467.
87. Mulatero, P., Panarelli, M., Schiavone, D., Rossi, A., Mengozzi, G., Kenyon, C.J., Chiandussi, L. Veglio, F. (1997) Impaired cortisol binding to glucocorticoid receptors in hypertensive patients. Hypertension, 30, 1274 1278.
88. Stevens, A., Ray, D.W., Zeggini, E., John, S., Richards, H.L., Griffiths, C.E. Donn, R. (2004) Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. Journal of Clinical Endocrinology and Metabolism, 89, 892 897.
89. Laragh, J.H. (2001) Abstract, closing summary, and table of contents for Laragh's 25 lessons in pathophysiology and 12 clinical pearls for treating hypertension. American Journal of Hypertension, 14, 1173 1177.
90. DiBona, G.F. Sawin, L.L. (1984) Renal tubular site of action of felodipine. Journal of Pharmacological and Experimental Therapy, 228, 420 424.
91. Blumenfeld, J.D. Laragh, J.H. (1998) Renin system analysis: A rational approach for the diagnosis and treatment of the individual patient. American Journal of Hypertension, 11, 894 896.
92. Nicholson, J.P., Resnick, L.M., Pickering, T.G., Marion, R.M., Sullivan, P. Laragh, J.H. (1985) Relationship of blood pressure response and the renin-angiotensin system to first dose prazosin. American Journal of Medicine, 78, 241 244.
93. Bolli, P., Amann, F.W. Buhler, F.R. (1980) Antihypertensive response to post-synaptic alpha-blockade with prazosin in low and normal renin patients. Hypertension, 2, S399 S405.
94. Buhler, F.R., Bolli, P., Kiowski, W., Erne, P., Hulthen, U.L. Block, L.H. (1984) Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high renin and calcium entry blockers for low-renin patients. American Journal of Medicine, 77, 36 42.
95. Rosenthal, J., Jaeger, H. Arlart, I. (1978) Effect of prazosin on blood pressure and plasma renin activity in man. Clinical Science and Molecular Medicine Supplements, 4, 337s 339s.
96. Flack, J.M., Oparil, S., Pratt, J.H., Roniker, B., Garthwaite, S., Kleiman, J.H., Yang, Y., Krause, S.L., Workman, D. Saunders, E. (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. Journal of the American College of Cardiology, 41, 1148 1155.
97. Weinberger, M.H., White, W.B., Ruilope, L.M., MacDonald, T.M., Davidson, R.C., Roniker, B., Patrick, J.L. Krause, S.L. (2005) Effects of eplerenone versus losartan in patients with low-renin hypertension. American Heart Journal, 150, 426 433.
98. Mahmud, A., Mahgoub, M., Hall, M. Feely, J. (2005) Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? American Journal of Hypertension, 18, 1631 1635.
99. Williams, B., Poulter, N.R., Brown, M.J., Davis, M., McInnes, G.T., Potter, J.F., Sever, P.S., Thom, S.M. BHS guidelines working Party, for the British Hypertension Society 2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. British Medical Journal, 328, 634 640.
100. Stump, C.S., Hamilton, M.T. Sowers, J.R. (2006) Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clinic Proceedings, 81, 796 806.
101. Dickerson, J.E., Hingorani, A.D., Ashby, M.J., Palmer, C.R. Brown, M.J. (1999) Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet, 353, 2008 2113.
102. Preston, R.A., Materson, B.J., Reda, D.J., Williams, D.W., Hamburger, R.J., Cushman, W.C. Anderson, R.J. (1998) Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Journal of the American Medical Association, 280, 1168 1172.
103. Chapman, A.B., Schwartz, G.L., Boerwinkle, E. Turner, S.T. (2002) Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney International, 61, 1047 1055.
104. Sareli, P., Radevski, I.V., Valtchanova, Z.P., Libhaber, E., Candy, G.P., Den Hond, E., Libhaber, C., Skudicky, D., Wang, J.G. Staessen, J.A. (2001) Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Archives of International Medicine, 161, 965 971.
105. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T. Jr., Roccella, E.J., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee 2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 Report. Journal of the American Medical Association, 289, 2560 2571.
106. Calhoun, D.A., Zaman, M.A. Nishizaka, M.K. (2002) Resistant hypertension. Current Hypertension Reports, 4, 221 228.
107. Lim, P.O., Young, W.F. MacDonald, T.M. (2001) A review of the medical treatment of primary aldosteronism. Journal of Hypertension, 19, 363 366.
108. Ouzan, J., Péraut, C., Lincoff, A.M., Carré, E. Mertes, M. (2002) The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension, 15, 333 339.
109. Nishizaka, M.K. Calhoun, D.A. (2005) The role of aldosterone antagonists in the management of resistant hypertension. Current Hypertension Reports, 7, 343 347.
110. Eide, I.K., Torjesen, P.A., Drolsum, A., Babovic, A. Lilledahl, N.P. (2004) Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension, 22, 2217 2226.
111. Naudzhunas, A., Bagdonas, G., Yankauskene, L. Kazanavichus, G. (2006) Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension. Terapevticheski Arkhiv, 78, 61 64.
112. Nishizaka, M.K., Zaman, M.A. Calhoun, D.A. (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. American Journal of Hypertension, 16, 925 930.
113. National Institute for Health Clinical Excellence (NICE) Clinical Guideline 34 2005) Hypertension: management of hypertension in adults in primary care: partial update. http://www.nice.org.uk/CG034guidance.
114. Lindholm, L.H., Carlberg, B., Samuelsson, O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 366, 1545 1553.